MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
INKT EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
MiNK Therapeutics, Inc.NASDAQ: INKT
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.57, compared with -$0.7 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.83.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 1 analysts of -$2.75 (+6.3%) for the fiscal year ending Dec 2026, a step up from the -4.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.57-3.6% QoQ
- Last fiscal yearDec 2025
- -$2.93-4.6% YoY
- LTMMar 2026
- -$2.83-11.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +18.6% | +43.4% | +24.8 pp |
| 1 year | -4.6% | +6.3% | +11.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (2.93) USD
- Year-over-year change
- -4.6%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.93) | -4.6% |
| FY2024 | 2024-12-31 | (2.80) | +57.2% |
| FY2023 | 2023-12-31 | (6.54) | +21.3% |
| FY2022 | 2022-12-31 | (8.31) | +8.0% |
| FY2021 | 2021-12-31 | (9.03) | — |
EPS (Diluted) vs competitors
How INKT compares with its peers on the latest reported figures
- INKT's LTM Mar 2026 EPS (Diluted) of -$2.83 is the 8th highest of the 9 companies compared; the peer median is -$0.9.
- Its year-over-year change of -11.4% is the 7th highest of 9, against a peer median of +36.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.02 | +100.6% | — | |
| LTM Mar 2026 | -$0.38 | +2.9% | — | |
| LTM Mar 2026 | -$0.58 | +34.8% | — | |
| LTM Jun 2026 | -$0.73 | +55.2% | — | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$1.07 | -124.9% | — |
| LTM Mar 2026 | -$1.28 | +38.9% | — | |
| LTM Mar 2026 | -$1.62 | -19.1% | — | |
| LTM Mar 2026 | -$2.83 | -11.4% | — | |
| LTM Mar 2026 | -$37.6 | +62.6% | — | |
| Peer median (excluding INKT) | -$0.9 | +36.9% | — | |
Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| Gross Profit | (77.96K) | (121.75K) | (204.62K) | (215.44K) | (181.75K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.97M | 23.12M | 15.49M | 6.34M | 5.76B |
| Selling, General & Admin | 4.56M | 7.71M | 7.43M | 4.1M | 6.73B |
| Operating Expenses | 18.53M | 30.83M | 22.72M | 10.43M | 12.31M |
| Depreciation & Amortization | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| EBITDA | (27.7M) | (27.87M) | (22.25M) | (10.57M) | (12.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.61M) | (30.95M) | (22.92M) | (10.65M) | (12.49M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 2.43K | 253.32K | 463.26K | 172.57K | 180.25K |
| Interest Expense | 2.43M | 253.32K | 0 | 0 | 0 |
| Other Income / Expenses | (11.61M) | 2.96M | 463.25K | (134.56K) | (6.96K) |
| Income Before Tax | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (9.03) | (8.31) | (6.54) | (2.90) | (2.93) |
| EPS (Diluted) | (9.03) | (8.31) | (6.54) | (2.80) | (2.93) |
| Weighted Avg Shares | 3.35M | 3.37M | 3.44M | 3.74M | 4.27M |
| Weighted Avg Shares (Diluted) | 3.35M | 3.37M | 3.44M | 3.86M | 4.27M |
MiNK Therapeutics, Inc.
NASDAQ:INKT
Intrinsic Alpha fair value
Locked
Current Price
$10.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.